---
title: "Nuvectis Pharma Jumps 20% To 52-Week High — Here's Why NVCT Stock Is Trending"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290525332.md"
description: "Nuvectis Pharma (NVCT) shares surged nearly 20% to a 52-week high of $16.53 following a licensing deal with Haisco Pharmaceutical Group. The agreement grants Nuvectis exclusive ex-China rights to clinical-stage compounds NXP100 and NXP200, expanding its pipeline for complement-mediated diseases and cancer. Under the terms, Haisco is eligible for up to $40 million in upfront payments and potential milestone payments totaling $1.421 billion."
datetime: "2026-06-23T06:30:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290525332.md)
  - [en](https://longbridge.com/en/news/290525332.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290525332.md)
generator: "portal-rs"
---

# Nuvectis Pharma Jumps 20% To 52-Week High — Here's Why NVCT Stock Is Trending

**Nuvectis Pharma, Inc.** (NASDAQ:NVCT) shares are trending on Monday.

NVCT shares surged 19.61% during Monday’s regular trading session to close at $16.53.

The stock slipped slightly in after-hours trading, falling 2.90% to $16.05.

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing treatments for complement-related diseases and cancer.

Its pipeline includes NXP100, a complement Factor B inhibitor, and cancer drug candidates NXP900 and NXP200.

## **Portfolio Expansion Drives Rally**

The move higher came after Nuvectis announced a strategic portfolio expansion through a license agreement with **Haisco Pharmaceutical Group** for exclusive ex-China rights to two clinical-stage compounds.

The deal adds NXP100, a late-stage complement Factor B inhibitor for complement-mediated diseases, and NXP200, a paradox-breaker BRAF inhibitor for advanced cancers, to the company’s pipeline.

Under the agreement, Haisco will receive up to $40 million in upfront and near-term payments and may receive up to $1.421 billion in milestone payments, plus royalties.

 **Read Also: Nexentis Technologies Soars 156% Before Falling 46% After Hours — Here’s Why NXTS Stock Is Trending** 

## **Trading Metrics, Technical Analysis**

Nuvectis has a market capitalization of $438.47 million, a 52-week high of $16.64, and a 52-week low of $5.55.

The stock has gained 107.66% over the past 12 months.

Currently, the stock is trading at about 98.9% of its 52-week range.

**Benzinga Edge Stock Rankings** indicate that Nuvectis has a positive price trend across the short, medium and long term.

***Disclaimer:** This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.*

 **Read Also: Elon Musk And Tesla AI Chief Fire Back At Reports Linking FSD To Fatal Texas Crash As NHTSA Launches Probe** 

*Photo Courtesy: Golden Dayz on Shutterstock.com*

### Related Stocks

- [NVCT.US](https://longbridge.com/en/quote/NVCT.US.md)
- [002653.CN](https://longbridge.com/en/quote/002653.CN.md)
- [NXTS.US](https://longbridge.com/en/quote/NXTS.US.md)
- [TSLA.US](https://longbridge.com/en/quote/TSLA.US.md)

## Related News & Research

- [Nuvectis Pharma sets up $200 million at-the-market equity program with Jefferies](https://longbridge.com/en/news/296650648.md)
- [China's Haisco Gets China’s Nod for Rare Blood Disorder Drug](https://longbridge.com/en/news/293607538.md)
- [Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004](https://longbridge.com/en/news/296680419.md)
- [Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.](https://longbridge.com/en/news/296643850.md)
- [iSpecimen ships hundreds of cancer blood specimens for international research order within three weeks](https://longbridge.com/en/news/296531044.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**